We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The onboard reagents deliver specifications with no culture confirmation required for negative results, unless symptoms persist or there is an outbreak of acute rheumatic fever. Read More
The program aims to validate how a pharmaceutical version of Dronabinol, an FDA-approved cannabinoid being developed by Insys, can be delivered through Senzer’s inhaler device. Read More